Entrada Therapeutics reported revenue of $0.90M and net income of -$42.94M for the quarter ended Jun 2026, down 53.9% year over year. This income statement covers 24 quarters of results from Sep 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 1.48M | 6.27M | 31.26M | 31.28M | 31.33M | 31.39M | 33.13M | 33.21M | 33.34M | 33.44M | 33.60M | 37.17M | 37.40M | 37.57M | 37.94M | 38.03M | 38.22M | 38.28M | 38.82M | 38.94M | ||||
| Revenue & cost | ||||||||||||||||||||||||
| Revenue | 25.26M | 18.17M | 43.73M | 41.85M | 59.12M | 94.69M | 19.57M | 37.40M | 20.56M | 1.95M | 1.61M | 1.30M | 0.88M | 0.90M | ||||||||||
| Operating items | ||||||||||||||||||||||||
| Research & DevelopmentR&D | 10.51M | 12.36M | 15.72M | 16.25M | 18.96M | 15.69M | 23.10M | 26.30M | 22.19M | 28.29M | 28.61M | 32.03M | 31.26M | 33.41M | 32.07M | 37.88M | 38.36M | 33.96M | 33.05M | 35.37M | ||||
| Selling, General & AdministrativeSG&A | 3.85M | 6.10M | 6.43M | 7.33M | 6.98M | 9.89M | 7.94M | 8.17M | 7.53M | 8.65M | 9.40M | 9.24M | 9.97M | 9.86M | 10.27M | 10.92M | 10.30M | 9.55M | 10.12M | 10.49M | ||||
| Operating ExpensesOpex | 14.36M | 18.46M | 22.15M | 23.58M | 25.94M | 25.58M | 31.04M | 34.47M | 29.72M | 36.94M | 38.01M | 41.27M | 41.23M | 43.27M | 42.35M | 48.80M | 48.66M | 43.51M | 43.18M | 45.86M | ||||
| Operating IncomeOp. Inc | -14.36M | -18.46M | -22.15M | -23.58M | -25.94M | -25.58M | -5.78M | -16.30M | 14.01M | 4.91M | 21.11M | 53.42M | -21.66M | -5.87M | -21.79M | -46.85M | -47.05M | -42.21M | -42.30M | -44.96M | ||||
| EBIT | -14.36M | -18.46M | -22.15M | -23.58M | -25.94M | -25.58M | -5.78M | -16.30M | 14.01M | 4.91M | 21.11M | 53.42M | -21.66M | -5.87M | -21.79M | -46.85M | -47.05M | -42.21M | -42.30M | -44.96M | ||||
| Non-operating items | ||||||||||||||||||||||||
| Interest & Investment IncomeInt & Inv Inc | -0.07M | 0.01M | 0.48M | 0.40M | 0.80M | 0.95M | 2.66M | 4.22M | 4.05M | 4.29M | 4.21M | 4.37M | 5.77M | 5.13M | 4.44M | 3.92M | 3.57M | 3.14M | 2.62M | 2.23M | ||||
| Other Non Operating IncomeOther Non Op Inc. | -0.07M | 0.01M | 0.48M | 0.40M | 0.80M | 0.95M | 2.66M | 4.22M | 4.05M | 4.29M | 4.21M | 4.37M | 5.77M | 5.13M | 4.44M | 3.92M | 3.57M | 3.14M | 2.62M | 2.23M | ||||
| Net income details | ||||||||||||||||||||||||
| EBT | -14.43M | -18.45M | -21.67M | -23.18M | -25.14M | -24.63M | -3.12M | -12.08M | 18.06M | 9.24M | 25.33M | 57.79M | -15.89M | -0.72M | -17.35M | -42.92M | -43.48M | -39.07M | -39.68M | -42.73M | ||||
| Tax ProvisionsTaxes | 3.60M | 13.85M | -17.40M | 18.74M | 1.83M | 2.80M | -1.90M | -1.83M | 0.18M | 0.70M | 0.09M | 0.04M | 0.04M | |||||||||||
| Profit After TaxPAT | -14.43M | -18.49M | -21.67M | -23.18M | -25.62M | -23.94M | -6.67M | -25.93M | 35.97M | -11.11M | 23.50M | 55.03M | -14.03M | 0.35M | -17.35M | -43.14M | -44.13M | -39.16M | -39.72M | -42.94M | ||||
| Income from Continuing OperationsIncome (Continuing) | -14.43M | -18.45M | -21.67M | -23.18M | -25.14M | -24.63M | -6.72M | -25.93M | 35.46M | -9.50M | 23.50M | 54.99M | -13.99M | 1.10M | -17.35M | -43.10M | -44.18M | -39.16M | -39.72M | -42.76M | ||||
| Consolidated Net IncomeConsol Net Inc. | -14.43M | -18.45M | -21.67M | -23.18M | -25.14M | -24.63M | -6.72M | -25.93M | 35.46M | -9.50M | 23.50M | 54.99M | -13.99M | 1.10M | -17.35M | -43.10M | -44.18M | -39.16M | -39.72M | -42.76M | ||||
| Income towards Parent CompanyParent Net Inc | -14.43M | -18.45M | -21.67M | -23.18M | -25.14M | -24.63M | -6.72M | -25.93M | 35.46M | -9.50M | 23.50M | 54.99M | -13.99M | 1.10M | -17.35M | -43.10M | -44.18M | -39.16M | -39.72M | -42.76M | ||||
| Net Income towards Common StockholdersNet Income | -14.43M | -18.45M | -21.67M | -23.18M | -25.14M | -24.63M | -6.72M | -25.93M | 35.46M | -9.50M | 23.50M | 54.99M | -13.99M | 1.10M | -17.35M | -43.10M | -44.18M | -39.16M | -39.72M | -42.76M | ||||
| Additional items | ||||||||||||||||||||||||
| EPS (Basic) | -9.78 | -2.94 | -0.69 | -0.74 | -0.80 | -0.79 | -0.21 | -0.78 | 1.07 | -0.29 | 0.70 | 1.61 | -0.34 | 0.03 | -0.42 | -1.04 | -1.07 | -0.95 | -0.95 | -1.01 | ||||
| EPS (Diluted) | -9.78 | -2.94 | -0.69 | -0.74 | -0.80 | -0.79 | -0.21 | -0.78 | 1.02 | -0.29 | 0.68 | 1.55 | -0.34 | 0.03 | -0.42 | -1.04 | -1.07 | -0.95 | -0.95 | -1.01 | ||||
| Shares Outstanding | 1.48M | 6.27M | 31.25M | 31.28M | 31.30M | 31.29M | 32.37M | 33.16M | 33.28M | 33.05M | 33.50M | 34.18M | 40.63M | 37.31M | 41.07M | 41.34M | 41.46M | 41.37M | 41.84M | 42.22M | ||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 1.48M | 6.27M | 31.25M | 31.28M | 31.30M | 31.29M | 32.37M | 33.16M | 34.78M | 33.05M | 34.79M | 35.51M | 40.63M | 39.00M | 41.07M | 41.34M | 41.46M | 41.37M | 41.84M | 42.22M | ||||
| EBITDA | -14.36M | -18.46M | -22.15M | -23.58M | -25.94M | -25.58M | -5.78M | -16.30M | 14.01M | 4.91M | 21.11M | 53.42M | -21.66M | -5.87M | -21.79M | -46.85M | -47.05M | -42.21M | -42.30M | -44.96M | ||||
| Tax Rate | -115.27 | -114.62 | -96.33 | 202.80 | 7.23 | 4.85 | 11.96 | 252.62 | -0.41 | -1.61 | -0.24 | -0.10 | -0.08 |